Kontakt 2010, 12(3):343-351 | DOI: 10.32725/kont.2010.047

KanabinoidyPopularizace vědy

Lenka Milfortová
Jihočeská univerzita v Českých Budějovicích, Zdravotně sociální fakulta, katedra radiologie a toxikologie

Received: March 5, 2010; Accepted: September 6, 2010; Published: October 20, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Milfortová L. Kanabinoidy. Kontakt. 2010;12(3):343-351. doi: 10.32725/kont.2010.047.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. APPENDINO, G., GIBBONS, S., GIANA, A., PAGANI, A., GRASSI, G., STAVRI, M., SMITH, E., RAHMAN, M. M.: Antibacterial cannabinoids from Cannabis sativa: a structure-activity study. J. Nat. Prod. 2008, vol. 71, p. 1427-1430. Go to original source... Go to PubMed...
    2. AVRAHAM, Y., BEN-SHUSHAN, D., BREUER, A., ZOLOTAREV, O., OKON, A., FINK, N., KATZ, V., BERRY, E. M.: Very low doses of delta 8-THC increase food consumption and alter neurotransmitter levels following weight loss. Pharmacol. Biochem. Behav. 2004, vol. 77, p. 675-684. Go to original source... Go to PubMed...
    3. BEAULIEU, P.: Effects of nabilone, a synthetic cannabinoid, on postoperative pain. Can. J. Anaesth. 2006, vol. 53, p. 769-775. Go to original source... Go to PubMed...
    4. BERLACH, D. M., SHIR, Y., WARE, M. A.: Experience with the synthetic cannabinoid nabilone in chronic noncancer pain. Pain Med. 2006, vol. 7, p. 25-29. Go to original source... Go to PubMed...
    5. BHATTACHARYYA, S., MORRISON, P. D., FUSAR-POLI, P., MARTIN-SANTOS, R., BORGWARDT, S., WINTON-BROWN, T., NOSARTI, C., O' CARROLL, C. M., SEAL, M., ALLEN, P., MEHTA.M.A., STONE, J. M.: Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology Neuropsychopharmacology. 2010, vol. 35, p. 764-774. Go to original source... Go to PubMed...
    6. BOOTH, M.: Cannabis: A History, 2005. Macmillan Publ. Random House, Inc. ISBN 978-0-312-42497-7.
    7. BRUINSMA, K., TAREN, D. L.: Chocolate: food or drug? J. Am. Diet. Assoc. 1999, vol. 99, p. 1249-1256. Go to original source... Go to PubMed...
    8. CABALLERO, A. E.: Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obes Res 2003;11:1278-89. Go to original source... Go to PubMed...
    9. DALTON, G. D., BASS, C. E., VAN HORN, C. G., HOWLETT, A. C.: Signal transduction via cannabinoid receptors. CNS Neurol. Disord. Drug Targets. 2009, vol. 8, p. 422-431. Go to original source... Go to PubMed...
    10. DAVIS, M. P.: Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain. Expert Opin. Investig. Drugs. 2008, vol. 17, p. 85-95. Go to original source... Go to PubMed...
    11. DE BACKER, B., DEBRUS, B., LEBRUN, P., THEUNIS, L., DUBOIS, N., DECOCK, L., VERSTRAETE, A., HUBERT, P., CHARLIER, C.: Innovative development and validation of an HPLC/DAD method for the qualitative and quantitative determination of major cannabinoids in cannabis plant material. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2009, vol. 877, p. 4115-4124. Go to original source... Go to PubMed...
    12. DE JONG, F. A.: Medicinal use of cannabis in the Netherlands: towards a responsible pattern of use. [Article in Dutch] Ned. Tijdschr. Geneeskd. 2009, vol. 153, p. B23. Go to PubMed...
    13. DENNIS, I., WHALLEY, B. J., STEPHENS, G. J.: Effects of Delta9-tetrahydrocannabivarin on [35S] GTPgammaS binding in mouse brain cerebellum and piriform cortex membranes. Br. J. Pharmacol. 2008, vol. 154, p. 1349-1358. Go to original source... Go to PubMed...
    14. DEVANE, W. A., HANUŠ, L., BREUER A., PERTWEE, R. G., STEVENSON, L. A., GRIFFIN, G., GIBSON, D., MANDELBAUM, A., ETINGER, A., MECHOULAM, R.: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, vol. 258, p. 1882-1884. Go to original source... Go to PubMed...
    15. DI TOMASO, E., BELTRAMO, M., PIOMELLI, D.: Brain cannabinoids in chocolate. Nature. 1996, vol. 382, p. 677-678. Go to original source... Go to PubMed...
    16. DOWNER, E. J., CAMPBELL, V. A.: Phytocannabinoids, CNS cells and development: a dead issue? Drug Alcohol Rev. 2010, vol. 29, p. 91-98. Go to original source... Go to PubMed...
    17. FERNANDEZ, J. R., ALLISON, D. B.: Rimonabant Sanofi-Synthelabo. Curr Opin Investig Drugs 2004; 5:430-435. Go to PubMed...
    18. FIŠAR, Z.: Endokanabinoidy. Chem. Listy 2006, vol. 100, p. 314-322.
    19. FIŠAR, Z.: Phytocannabinoids and endocannabinoids. Curr. Drug Abuse Rev. 2009, vol. 2, p. 51-75. Go to original source... Go to PubMed...
    20. FUSAR-POLI, P., CRIPPA, J. A., BHATTACHARYYA, S., BORGWARDT, S. J., ALLEN, P., MARTIN-SANTOS, R., SEAL, M., SURGULADZE, S. A., O'CARROL, C., ATAKAN, Z., ZUARDI, A. W., MCGUIRE, P. K.: Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch. Gen. Psychiatry. 2009, vol. 66, p. 95-105. Go to original source... Go to PubMed...
    21. GALAL, A. M., SLADE, D., GUL, W., EL-ALFY, A. T., FERREIRA, D., ELSOHLY, M. A.: Naturally occurring and related synthetic cannabinoids and their potential therapeutic applications. Recent Pat. CNS Drug Discov. 2009, vol. 4, p. 112-136. Go to original source... Go to PubMed...
    22. GUINDON, J., HOHMANN, A. G.: The endocannabinoid system and pain. CNS. Neurol Disord. Drug Targets. 2009, vol. 8, p. 403-421. Go to original source... Go to PubMed...
    23. HANUŠ, L. O., MECHOULAM, R.: Novel natural and synthetic ligands of the endocannabinoid system. Curr. Med. Chem. 2010 Feb 18. [Epub ahead of print] Go to original source... Go to PubMed...
    24. HILL, A. J., WESTON, S. E., JONES, N. A., SMITH, I., BEVAN, S. A., WILLIAMSON, E. M., STEPHENS, G. J., WILLIAMS, C. M., WHALLEY, B. J.: Delta-Tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure activity in adult rats. Epilepsia. 2010 Feb 26. [Epub ahead of print] Go to original source... Go to PubMed...
    25. HILTUNEN, A. J., JÄRBEM, T. U., KAMKARM, M. R., ARCHERM, T.: Behaviour in rats maintained by low differential reinforcement rate: effects of delta 1-tetrahydrocannabinol, cannabinol and cannabidiol, alone and in combination. Neuropharmacology. 1989, vol. 28., p. 183-189.
    26. HOLLEY, J. H., HADLEY, K. W., TURNER, C. E.: Constituents of Cannabis sativa L. XI: Cannabidiol and cannabichromene in samples of known geographical origin. J Pharm Sci. 1975, vol. 64, p. 892-894. Go to original source... Go to PubMed...
    27. HRDINA, V., HRDINA, R., JAHODÁŘ, L., MARTINEC, Z., MĚRKA, V.: Přírodní toxiny a jedy. Galén, Praha 2004, 302 s.
    28. IUVONE, T., ESPOSITO, G., DE FILIPPIS, D., SCUDERI, C., STEARDO, L.: Cannabidiol: a promising drug for neurodegenerative disorders? CNS Neurosci. Ther. 2009, vol. 15, p. 65-75. Go to original source... Go to PubMed...
    29. JAMES, J. S.: Marijuana and chocolate. AIDS Treat News. 1996, no 257, p. 3-4.
    30. JANERO, D. R., MAKRIYANNIS, A.: Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. Expert Opin Emerg Drugs. 2009, vol. 14, p. 43-65. Go to original source... Go to PubMed...
    31. KAPEGHIAN, J. C., JONES, A. B., MURPHY, J. C., ELSOHLY, M. A., TURNER, C. E.: Effect of cannabichromene on hepatic microsomal enzyme activity in the mouse. Gen. Pharmacol. 1983, vol. 14, p. 361-363. Go to original source... Go to PubMed...
    32. KAVALÍROVÁ, A., VIŠŇOVSKÝ, P.: Use of marijuana in pharmacy students (2000-2005). Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 2005, vol. 149, p. 477-480. Go to original source...
    33. KVASNIČKA, T.: Endokanabinoidní systém a interference s trombogenézou. Vnitř. Lek. 2010, vol. 56, s. 127-129.
    34. LI, H. L., LIN, H.: An archeological and historica account of cannabis in China. Econ. Botan. 1974, vol. 28, p. 437-447. Go to original source...
    35. LURIE, I. S., MEYERS, R. P., CONVER, T. S.: Capillary electrochromatography of cannabinoids. Anal Chem. 1998, vol. 70, p. 3255-3260. Go to original source... Go to PubMed...
    36. MARCO, E. M., VIVEROS, M. P.: The critical role of the endocannabinoid system in emotional homeostasis: avoiding excess and deficiencies. Mini Rev. Med. Chem. 2009, vol. 9, p. 1407-1415. Go to original source... Go to PubMed...
    37. MARIMOUTOU, C., QUEYRIAUX, B., MICHEL, R., VERRET, C., HAUS-CHEYMOL, R., MAYET, A., DEPARIS, X., BOUTIN, J. P.: Survey of alcohol, tobacco, and cannabis use in the French army. J. Addict. Dis. 2010, vol. 29, p. 98-106. Go to original source... Go to PubMed...
    38. MERKUS, F. W.: Cannabivarin and tetrahydrocannabivarin, two new constituents of hashish. Nature. 1971, vol. 232, p. 579-580. Go to original source... Go to PubMed...
    39. MIOVSKÁ, L., MIOVSKÝ, M.: Vliv užívání konopných drog na kognitivní funkce jejich uživatel: zhodnocení aktuálního stavu výzkumu. Psychiatrie 2008, vol. 12, s. 93-100.
    40. MIOVSKÝ, M., ŠŤASTNÁ, L., ŘEHAN, V.: Aktuální přehled stavu užívání konopných drog v České republice z perspektivy školních a celopopulačních studií. Psychiatrie 2004, vol. 3, s. 280-285.
    41. MOUDRÝ, J., STRAŠIL, Z.: Alternativni plodiny. Zemědělská fakulta JU České Budějovice 1996, 68 s.
    42. MOUSLECH, Z., VALLA, V.: Endocannabinoid system: An overview of its potential in current medical practice. Neuro.Endocrinol Lett. 2009, vol. 30, p. 153-179.
    43. PARAKH, P.: Adverse health effects of non-medical cannabis use. Lancet 2010, vol. 375, p. 196-197. Go to original source... Go to PubMed...
    44. PERTWEE, R. G.: Pharmacological action of cannabinoids. HEP 2005, vol. 168, p. 1-51. Go to original source... Go to PubMed...
    45. REGGIO, P. H., SELTZMAN, H. H., COMPTON, D. R, PRESCOTT, W. R. Jr, MARTIN, B. R.: Investigation of the role of the phenolic hydroxyl in cannabinoid activity. Mol Pharmacol. 1990, vol. 38, p. 854-862.
    46. REGGIO, P. H., MCGAUGHEY, G. B., ODEAR, D. F., SELTZMAN, H. H., COMPTON, D. R., MARTIN, B. R.: A rational search for the separation of psychoactivity and analgesia in cannabinoids. Pharmacol. Biochem. Behav. 1991, vol. 40, p. 479-486. Go to original source... Go to PubMed...
    47. ROBINSON, R.: Velká kniha o konopí. Volvox Globator, 1997, orig. The Great Book of Hemp, nakl. Park Street Press, Vermont 1996.
    48. ROSENSON, R. S.: Role of the endocannabinoid system in abdominal obesity and the implications for cardiovascular risk. Cardiology. 2009, vol. 114, p. 212-225. Go to original source... Go to PubMed...
    49. ROXBURGH, A., HALL, W. D., DEGENHARDT, L., MCLAREN, J., BLACK, E., COPELAND, J., MATTICK, R. P.: The epidemiology of cannabis use and cannabis-related harm in Australia 1993-2007. Addiction. 2010 Mar 12. [Epub ahead of print] Go to original source... Go to PubMed...
    50. RUSSO, E., GUY, G.: A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannaabidiol. Med. Hypoth. 2006, vol. 66, p. 234-246. Go to original source... Go to PubMed...
    51. ŘEHÁK, M.: Problematika obchodu s konopnými drogami ve světě a v ČR. Diplomová práce, VŠE Praha 2001, 75 s.
    52. SHARIR, H., ABOOD, M. E.: Pharmacological characterization of GPR55, a putative cannabinoid receptor. Pharmacol. Ther. 2010 Mar 16. [Epub ahead of print] Go to original source... Go to PubMed...
    53. SCHEEN, A. J.: CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant. J Neuroendocrinol. 2008, vol. 20, Suppl 1, p. 139-146. Go to original source... Go to PubMed...
    54. SLATKIN, N. E.: Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis. J. Support. Oncol. 2007, vol., Suppl 3, p. 1-9.
    55. TOUWN, M.: The religious and medicinal use of Cannabis in China, India and Tibet. J. Psychoactive Drugs 1981, vol. 13, p. 23-34. Go to original source... Go to PubMed...
    56. TRAYNOR, J.: Regulator of G protein-signaling proteins and addictive drugs. Ann. N. Y. Acad. Sci. 2010, vol. 1187, p. 341-352. Go to original source... Go to PubMed...
    57. TURNER, C. E., HADLEY, K.: Constituents of Cannabis sativa L. II. Ansence of cannabidiol in an african variant. J. Pharm. Sci. 1973, vol. 62. p. 251-255. Go to original source... Go to PubMed...
    58. TURNER, C. E., HADLEY, K. W., FETTERMAN, P.: Constituents of Cannabis sativa L., VI: Propyl homologues in samples of known geographical origin. J. Pharm. Sci. 1973, vol. 62, p. 1739-1741. Go to original source... Go to PubMed...
    59. TYTGAT, J., VAN BOVEN, M., DAENENS, P.: Cannabinoid mimics in chocolate utilized as an argument in court. Int. J. Legal Med. 2000, vol. 113, p. 137-139. Go to original source... Go to PubMed...
    60. WARE, M. A., FITZCHARLES, M. A., JOSEPH, L., SHIR, Y.: The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth. Analg. 2010, vol. 110, p. 604-610. Go to original source... Go to PubMed...
    61. VARGA, E. V., GEORGIEVA, T., TUMATI, S., ALVES, I., SALAMON, Z., TOLLIN, G., YAMAMURA, H. I., ROESKE, W. R.: Functional selectivity in cannabinoid signaling. Curr. Mol. Pharmacol. 2008, vol. 1, p. 273-284. Go to original source...
    62. ZUARDI, A. W.: History of cannabis as a medicine: a review. Rev. Bras. Psiquiatr. 2006, vol. 28, p. 153-157. Go to original source... Go to PubMed...
    63. ZUARDI, A. W.: Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev. Bras. Psiquiatr. 2008, vol. 30, p. 271-280. Go to original source... Go to PubMed...

    Return to the content